Abstract:First-generation KRAS G12C inhibitors [G12Ci(s)], such as sotorasib and adagrasib, are limited by the depth and duration of clinical responses. One potential explanation for their modest clinical activity is the dynamic "cycling" of KRAS between its GDP- and GTP-bound states, raising controversy whether targeting the GDP-bound form can fully block this oncogenic driver. We herein report D3S-001, a second-generation GDP-bound G12Ci with faster target engagement (TE) kinetics, depletes cellular active KRAS G12C at sub-nanomolar concentrations, overcomes nucleotide cycling, and demonstrates durable anti-tumor activities preclinically and in a phase 1 clinical trial (NCT05410145). Covalent efficiency and TE kinetics were measured by SPR, LC-MS and ELISA. Anti-tumor efficacy was assessed in cell line-derived xenograft (CDX) and patient-derived xenograft or organoid (PDX or PDO) models. Activity in brain metastatic tumors and tumors with acquired resistance to sotorasib was investigated. Preclinically, D3S-001 exhibited exceptionally high covalent efficiency with a kinact/KI of 1.43 × 106 M−1s−1, the highest among all reported G12Ci(s) to date and a 20- to 70-fold improvement over adagrasib and sotorasib, respectively. In whole cells, D3S-001 depleted GTP-bound active KRAS G12C with an inactivation t1/2 of 5.8 minutes, allowing >95% TE (5x t1/2) in 30 minutes which is within the time required for epithelial growth factor (EGF) to induce KRAS GDP to GTP transition. By contrast, sotorasib and adagrasib required 3.7 and 2.8 hours, respectively, to reach 95% TE. In the presence of EGF, the ability of sotorasib and adagrasib to block KRAS was compromised by over 55%, whereas TE kinetics of D3S-001 was nearly unaffected, a unique feature differentiating D3S-001 from earlier GDP-bound G12Ci(s). The covalent efficiency of D3S-001 correlated with robust anti-tumor activity at sub-nanomolar concentrations and durable tumor regressions in CDX and PDX/PDO models of different cancer types. In a sotorasib-resistant PDX model, D3S-001 exhibited robust efficacy of tumor regression, while sotorasib and adagrasib showed no effect. Treatment with D3S-001 also resulted in sustained intracranial tumor remission in brain metastasis models. In the first-in-human trial of D3S-001, durable RECIST responses in patients were observed across all dose cohorts from 50 mg to 900 mg QD. Durable intracranial activity was also observed. Response rate and duration are reported in a companion clinical trial abstract submitted to this AACR meeting. In conclusion, D3S-001 is a second-generation GDP-bound KRAS G12Ci that overcomes GDP-to-GTP cycling. Its high covalent efficiency and rapid TE kinetics correlated with robust anti-tumor activity preclinically and translated into promising clinical activity with a high response rate and durable responses in a phase 1 trial. Citation Format: Jing Zhang, Sun Min Lim, Mi Ra Yu, Cheng Chen, Jia Wang, Wenqian Wang, Haopeng Rui, Jingtao Lu, Shun Lu, Tony Mok, Zhi Jian Chen, Byoung Chul Cho. D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6503.

In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

SCH 727965, a Novel Cyclin-Dependent Kinase Inhibitor, Has Potent Anti-Tumor Acitivity in a Wide-Spectrum of Human Tumor Xenograft Models

Discovery of Novel Glycogen Synthase Kinase-3Α Inhibitors: Structure-based Virtual Screening, Preliminary SAR and Biological Evaluation for Treatment of Acute Myeloid Leukemia.

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: Medicinal Chemistry Perspective

Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines

Development of a new analog of SGK1 inhibitor and its evaluation as a therapeutic molecule of colorectal cancer

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties

Abstract 4166: Small-molecule inhibition of glycogen synthase kinase-3 (GSK-3) increases the efficacy of anti-PD-L1 therapy in a murine model of microsatellite stable colorectal cancer (CRC); Therapeutic response correlates with T cell ratios and serum cytokine profiles in mice

Abstract 6503: D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities

Abstract #1740: Characterization of GSK1838705A, a Small Molecule Inhibitor of the Insulin-Like Growth Factor-1 Receptor and Anaplastic Lymphoma Kinase That Delays Growth of IGF-1R-dependent Tumors and Causes Regression of ALK-dependent Tumors in Vivo

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs